Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
about
Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study.Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot studyDosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trialComparison of hybrid volumetric modulated arc therapy (VMAT) technique and double arc VMAT technique in the treatment of prostate cancer.High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patientsPositional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy.A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.MRI of the prostate: clinical relevance and emerging applications.A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment.IMRT utilization in Ontario: qualitative deployment evaluation.Dosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer.Intensity modulated radiotherapy: advantages, limitations and future developments.External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity.A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy.Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists.Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging.Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives.Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.Treatments of exceptionally large prostate cancer patients with low-energy intensity-modulated photons.Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic trackingDosimetric Studies of Mixed Energy Intensity Modulated Radiation Therapy for Prostate Cancer Treatments
P2860
Q34646432-5D75E51F-80DE-4741-BCBB-5216CAFBCA13Q35684509-E66CF25B-B1A6-46B3-A94B-BF9F8F7E3405Q35844052-B038F439-E267-4857-9CF3-C90877896683Q36079275-E75B6584-3C8B-42CD-A597-1675DA3F0926Q36726326-4AD6D1F5-7429-4EA7-992B-18CDC1B482D5Q37364546-960FE864-EF0B-4B44-9871-CE853F5854E2Q37386325-2F5865AE-ABE8-4098-A9F1-2539AB82FAF2Q37601093-A9BA0BBE-7A80-4807-B863-703E5392616BQ37833011-5FF191AA-426D-47E9-8F97-8E8BB971DF39Q38356515-36919251-4FCE-419F-A786-D12E205F78FEQ39095094-7C596790-5894-4952-BB11-FE3ADBF9439FQ40160678-35536084-F996-4885-A103-70C2FDB6461CQ40361409-5D86916F-2287-4179-91AC-336585FFF89BQ41220988-C29117F3-1B13-48AE-980E-995EB845C615Q41897302-A096F5FC-16FC-4A74-9876-742AADB25585Q41997352-0BAFFFC9-C18D-4AA2-B2CB-C2EF1B7B7C9DQ42981640-6FF2D62D-77E7-4A97-883E-2E9DE7937BF6Q43478016-DF40B17D-C1A8-405F-94F1-EBDF96BCE516Q43824418-FD1E1AD5-C3AE-41AC-AF7C-0822B3D5EF68Q43979431-80E444BE-F1AC-4F35-AA17-CF41E514622CQ46961215-E6A088F7-7384-4B78-9543-9A1DAC7CD045Q48101934-9B378BE2-AFAF-457A-AC17-BC492885F463Q48113512-276A6D22-F64D-4606-9623-0D19E78C8E7FQ49026485-813CA474-B142-4CC0-9A68-352532388732Q55511975-C4460488-0AAB-4B0B-8DF8-E1C17765190CQ58130546-564CE834-14C2-4A6E-9A19-68E1984BF0B5Q59051507-387DAA75-C096-4733-B3B9-5981DF3CD097
P2860
Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@ast
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@en
type
label
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@ast
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@en
prefLabel
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@ast
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@en
P2093
P1476
Intensity-modulated radiothera ...... cute toxicity in 114 patients.
@en
P2093
Antony Verbaeys
Geert Villeirs
Gert De Meerleer
Luc Vakaet
Sabine Meersschout
Wilfried De Neve
Wim Oosterlinck
P304
P356
10.1016/J.IJROBP.2004.04.017
P407
P577
2004-11-01T00:00:00Z